News
MRI showed confluent bifrontal white matter lesions ... No neurofibrillary tangles or amyloid plaques were found in the parenchyma. Reactive gliosis, strong upregulation of microglia and multiple ...
investigated the relationship between anticoagulant use and the location and etiology of intracerebral hemorrhage (ICH), focusing on whether hypertensive microangiopathy or cerebral amyloid angiopathy ...
PET/CT, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis ...
Like lecanemab before it, donanemab’s path to market has been slow and rocky. In the U.S., the antibody received Food and Drug Administration approval about nine months ago, but only a few hundred ...
ARIA are side effects of anti-amyloid therapies that produce abnormal brain signals on MRI scans. They include fluid accumulation or microhemorrhages. “In the various studies of anti-amyloid ...
For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from the brains of people destined to develop Alzheimer’s dementia can ...
An early look at the phase 1b/2a data showed amyloid levels fell below a disease threshold in 81% of patients after 28 weeks. The Swiss drugmaker has identified the speed at which amyloid is ...
Both early-onset and late-onset Alzheimer's disease start with amyloid slowly collecting in the brain two decades before memory and thinking problems arise. Further, all trial results from these ...
The findings suggest -- for the first time in a clinical trial -- that early treatment to remove amyloid plaques from the brain many years before symptoms arise can delay the onset of Alzheimer's ...
Panelists discuss how amyloid-targeting therapies for Alzheimer disease represent a breakthrough drug class that works by binding to and removing beta-amyloid plaques through various mechanisms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback